Optimizing Clozapine Treatment: Part II

Psychopharm Review

Volumn 44, Issue 2, 2009, Pages 9-16

  Phansalkar, Sachin ^a,b   Osser, David N ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Taunton State Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIHISTAMINIC AGENT; ATENOLOL; BENZATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLONIDINE; CLOZAPINE; DIPHENHYDRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GLYCOPYRRONIUM BROMIDE; GUANFACINE; LAXATIVE; LITHIUM; METFORMIN; MODAFINIL; NEUROLEPTIC AGENT; NIZATIDINE; OLANZAPINE; PROPRANOLOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SERTRALINE; SIBUTRAMINE; TOPIRAMATE; TRIHEXYPHENIDYL; UNINDEXED DRUG; VALPROIC ACID;

ADD ON THERAPY; AGRANULOCYTOSIS; BENIGN CYCLIC NEUTROPENIA; BENIGN ETHNIC NEUTROPENIA; CARDIOMYOPATHY; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONSULTATION; DEATH; DIET SUPPLEMENTATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG PACKAGING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; ELECTROCARDIOGRAM; ETHNIC DIFFERENCE; EXERCISE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSALIVATION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INSULIN RESISTANCE; INTESTINE ISCHEMIA; INTESTINE OBSTRUCTION; LABORATORY TEST; LEUKOCYTE; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; MEGACOLON; METABOLIC DISORDER; MYOCARDITIS; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION; OBESITY; OBSESSIVE COMPULSIVE DISORDER; PARALYTIC ILEUS; POSITIVE SYNDROME; PRACTICE GUIDELINE; PSYCHOSIS; REBOUND; REBOUND EXACERBATION; REHYDRATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; TACHYCARDIA; WEIGHT GAIN;

EID: 77955615908     PISSN: 19369255     EISSN: None     Source Type: Trade Journal    
DOI: 10.1097/01.idt.0000343814.12380.d4     Document Type: Review

References (32)

1. Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry 1999;175:576-580.
2. Ghaznavi S, Nakic M, Rao P, et al. Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia. Am J Psychiatry 2008;165(7): 813-818.
3. Porter R, Mohamed A. Diurnal variation of neutropenia during clozapine treatment. Int J Neuropsychopharmacol 2006;9(3):373-374.
4. Esposito D, Chouinard G, Hardy P, et al. Successful initiation of clozapine treatment despite morning pseudoneutropenia. Int J Neuropsychopharmacol 2006;9(4): 489-491.
5. Kelly DL, Kreyenbuhl J, Dixon L, et al. Clozapine underutilization and discontinuation inAfricanAmericans due to leucopenia. Schizophr Bull 2007;33(5):1221-1224.
6. Fisher N, Baigent B. Treatment with clozapine. Black patients' low white cell counts currently mean that they cannot be treated. BMJ 1996;313(7067):1262.
7. Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol 1996;49(8):664-666.
8. Mathewson KA, Lindenmayer JP. Clozapine and granulocyte colony-stimulating factor: Potential for long-term combination treatment for clozapine-induced neutropenia. J Clin Psychopharmacol 2007;27(6):714-715.
9. Haag S, Rosenius S, Spigset O. Long-term combination treatment with clozapine and filgastrim in patients with clozapine-induced agranulocytosis. Int Clin Psychopharmacol 2003(3);18:173-174.
10. Kanaan RA, Kerwin RW. Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatry 2006;67(5):756-760.
11. Taylor D, Paton C, Kerwin R. Maudsley Prescribing Guidelines, 9th ed. New York: Taylor & Francis; 2007.
12. Warner B, Alphs L, Schaedelin J, et al. Clozapine and sudden death. Lancet 2000;355(9206):842.
13. Kilian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354(9193):1841-1845.
14. PianoMR.Alcoholic cardiomyopathy: Incidence, clinical characteristics, and pathophysiology. Chest 2002;121(5): 1638-1650.
15. Kang UG, Kwon JS, AhnYM, et al. Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry 2000;61(6):441-446.
16. Reinders J, ParsonageW, Lange D, et al. Clozapinerelated myocarditis and cardiomyopathy in anAustralian metropolitan psychiatric service. Aust N Z J Psychiatry 2004;38:915-922.
17. Roh S, Ahn DH, Nam JH, et al. Cardiomyopathy associated with clozapine. Exp Clin Psychopharmacol 2006;14(1):94-98.
18. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157(6):975-981.
19. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Schizophrenia Bull 2007;33(3):654-656. (Pubitemid 47343724)
20. Gihwala R, Golden G. Reduced salivation and improved condition: preliminary results from FOCUS registry of clozapine orally disintegrating tablets for schizophrenia. American PsychiatricAssociationAnnual Meeting New Research Poster NR 4-084, Washington, DC, May 6, 2008.
21. Chen CH, HuangMC, LuML.Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients. J Clin Psychopharmacology 2007;27(5):516-517.
22. Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjunct to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006;113(2):142-147.
23. Mitsonis CI, Dimopoulos NP, Mitropoulos PA, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(2):373-377.
24. Krassner M. Clozapine: Management of Adverse Effects: Quick Reference. East Hanover, NJ: Sandoz Pharmaceuticals Corp.; 1993.
25. Palmer SE, McLean RM, Ellis PM, et al. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 2008;69(5): 759-768.
26. Lu ML, Lane HY, Chen KP, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000;61(8):594-599.
27. Narendran R, Young CM, Valenti AM, et al. Is psychosis exacerbated by modafinil? Arch Gen Psychiatry 2002;59(3):292-293.
28. Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology 2006;185(3):265-273.
29. Cree A, Mir S, Fahy T. A review of the treatment options for clozapine-induced hypersalivation. Psychiatric Bull 2001;25:114-116.
30. De Haan L, Linszen DH, Gorsira R. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J Clin Psychiatry 1999;60(6):364-365.
31. Shiovitz TM, Welke TL, Tigael PD, et al. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 1996;22(4):591-595.
32. Miodownik C, Lerner V, Kibari A, et al. Effect of sudden clozapine discontinuation on management of schizophrenic patients: a retrospective controlled study. J Clin Psychiatry 2006;67(8):1204-1208.